Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sodium iothalamate I 125
- Development stage
- Approved
- Lead developer
- Iso-Tex Diagnostics
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Sodium iothalamate I 125 is a sterile, nonpyrogenic aqueous solution of the sodium salt of iothalamic acid labeled with the radioactive isotope iodine-125. It is used as a radiopharmaceutical diagnostic agent primarily for evaluating glomerular filtration rate (GFR) in renal function tests. The compound is administered intravenously and its clearance from plasma closely approximates that of inulin, making it an accurate marker for measuring GFR. Sodium iothalamate is filtered by the glomeruli without significant tubular secretion or reabsorption. The iodine-125 label emits low-energy gamma radiation suitable for detection with minimal radiation exposure to patients and staff[1][2][6]. Its high affinity for plasma proteins ensures vascular compartment retention during testing[6]. The drug is stable both in vitro and in vivo throughout diagnostic procedures.
- Brand names
- Glofil-125Glofil125Glofil 125
- Other names
- Sodium iotalamate (125I)iothalamic acid (I-125)sodium iothalamate (I-125)
Beyond the preview
Go deeper on sodium iothalamate I 125.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sodium iothalamate I 125.